The company has a patented immunotherapy platform called Hi-8™ PrimeBoost, which enables the rapid development of products to enhance immune responses against diseases. Oxxon has completed phase II clinical programs for melanoma and hepatitis B, and is currently working on a development program for HIV. Additionally, the company plans to collaborate with other companies to leverage its platform for therapeutic and preventative vaccine products. Oxxon Therapeutics is a mid-stage biotechnology company that focuses on developing immunotherapeutics using its proprietary Heterologous PrimeBoost approach. Founded in 1999, the company has successfully progressed its products to phase II clinical trials for melanoma and hepatitis B, and is also involved in pre-clinical product development through collaborations.